Hironobu Ihn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hironobu Ihn has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
K. Tamaki
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
2 shared publicationsK. Yamane
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
2 shared publicationsKunihiko Tamaki
University of Tokyo, Tokyo, Japan
1 shared publicationM. Jinnin
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
1 shared publicationM. Kubo
Department of Dermatology, Faculty of Medicine, University of Tokyo, Mita Hospital, Tokyo, Japan
1 shared publicationMasatoshi Jinnin
University of Tokyo, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 27 April 2007
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (5) , 1694-1705
Involvement of the constitutive complex formation of c‐Ski/SnoN with smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts
Objective: The principal effect of transforming growth factor β1 (TGFβ1) on mesenchymal cells is its stimulation of extracellular matrix synthesis. Previous reports indicated the significance of the autocrine TGFβ loop in the pathogenesis of scleroderma. The aim of this study was to examine c‐Ski and SnoN, principal molecules in the negative regulation of TGFβ signaling, to further understand the autocrine TGFβ loop in scleroderma.Methods: Levels of expression of c‐Ski/SnoN on cultured normal and scleroderma fibroblasts were determined by Western blotting, Northern blotting, and immunohistochemical staining. To determine the protein–protein interaction between c‐Ski/SnoN, Smads, and p300, immunoprecipitation was performed. A transient transfection assay was performed to measure promoter activity of the α2(I) collagen gene and the 3TP‐Lux plasmid construct.Results: Scleroderma fibroblasts exhibited increased c‐Ski/SnoN levels compared with normal fibroblasts, both in vivo and in vitro. Although c‐Ski/SnoN constitutively formed a complex with Smads by immunoprecipitation, the inhibitory effect of c‐Ski/SnoN on the promoter activity of human α2(I) collagen and 3TP‐Lux was impaired in scleroderma fibroblasts. Immunoprecipitation analyses also revealed that overexpressed c‐Ski/SnoN could not compete with p300 in these cells.Conclusion: These results indicate that impaired competition with p300 is the possible cause of dysfunction of c‐Ski/SnoN in scleroderma fibroblasts and that this might contribute to maintenance of the autocrine TGFβ loop in this disease.
- 27 April 2007
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (5) , 1694-1705
Open AccessInvolvement of the constitutive complex formation of c‐Ski/SnoN with smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts
Objective: The principal effect of transforming growth factor β1 (TGFβ1) on mesenchymal cells is its stimulation of extracellular matrix synthesis. Previous reports indicated the significance of the autocrine TGFβ loop in the pathogenesis of scleroderma. The aim of this study was to examine c‐Ski and SnoN, principal molecules in the negative regulation of TGFβ signaling, to further understand the autocrine TGFβ loop in scleroderma.Methods: Levels of expression of c‐Ski/SnoN on cultured normal and scleroderma fibroblasts were determined by Western blotting, Northern blotting, and immunohistochemical staining. To determine the protein–protein interaction between c‐Ski/SnoN, Smads, and p300, immunoprecipitation was performed. A transient transfection assay was performed to measure promoter activity of the α2(I) collagen gene and the 3TP‐Lux plasmid construct.Results: Scleroderma fibroblasts exhibited increased c‐Ski/SnoN levels compared with normal fibroblasts, both in vivo and in vitro. Although c‐Ski/SnoN constitutively formed a complex with Smads by immunoprecipitation, the inhibitory effect of c‐Ski/SnoN on the promoter activity of human α2(I) collagen and 3TP‐Lux was impaired in scleroderma fibroblasts. Immunoprecipitation analyses also revealed that overexpressed c‐Ski/SnoN could not compete with p300 in these cells.Conclusion: These results indicate that impaired competition with p300 is the possible cause of dysfunction of c‐Ski/SnoN in scleroderma fibroblasts and that this might contribute to maintenance of the autocrine TGFβ loop in this disease.
- 23 March 2007
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (5) , 1058-1060
High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma
- 23 March 2007
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (5) , 1058-1060
High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma
- 11 September 2005
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 154 (5) , 919-925
The expression levels and the differential expression of transforming growth factor-β receptors in dermatofibroma and dermatofibrosarcoma protuberans
Background Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are benign and intermediate malignant fibrotic dermal tumours, respectively. The contribution of transforming growth factor (TGF)‐β has been implicated in the progression of sclerosis in fibrotic diseases. Objectives To investigate the expression of TGF‐β receptors in these fibrotic tumours. Methods We examined the expression levels of TGF‐β type I and type II receptors (TGFβ‐RI and TGFβ‐RII) in DF and DFSP using in situ hybridization and immunohistochemical analysis. We also examined the expression of TGF‐β1 and collagen type I using immunohistochemical analysis. Results We detected strong expression of TGFβ‐RI and TGFβ‐RII on epidermis and epidermal appendages, moderate expression in vascular endothelial cells, smooth muscle cells and neural tissues, and weak expression in fibroblasts in normal skin sections. The expression levels of TGFβ‐RI and TGFβ‐RII were elevated in the tissue sections of DF in comparison with normal dermal sections using in situ hybridization and immunohistochemical staining. Furthermore, the expression of TGFβ‐RI and TGFβ‐RII was strong in spindle‐shaped cells around DF. The expression of TGFβ‐RI and TGFβ‐RII was decreased in DFSP in comparison with DF, and their expression was found to be homogeneous in each DFSP tumour cell. The staining for TGF‐β1 was found prominently on matrix and spindle‐shaped tumour cells of DF, and peripheral regions of DFSP. Weak expression of TGF‐β1 was found on normal skin or tumour cells in the central part of DFSP. Type I collagen expression was found on spindle‐shaped tumour cells in DF, but not in tumour cells of DFSP. Conclusions These results suggest the possibility that TGF‐β signalling may contribute to the fibrosis around DF, and that TGF‐β receptors may play important roles in TGF‐β signalling. The expression patterns of TGFβ‐RI and TGFβ‐RII may be helpful in distinguishing these diseases.
- 11 September 2005
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 154 (5) , 919-925
The expression levels and the differential expression of transforming growth factor-β receptors in dermatofibroma and dermatofibrosarcoma protuberans
Background Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are benign and intermediate malignant fibrotic dermal tumours, respectively. The contribution of transforming growth factor (TGF)‐β has been implicated in the progression of sclerosis in fibrotic diseases. Objectives To investigate the expression of TGF‐β receptors in these fibrotic tumours. Methods We examined the expression levels of TGF‐β type I and type II receptors (TGFβ‐RI and TGFβ‐RII) in DF and DFSP using in situ hybridization and immunohistochemical analysis. We also examined the expression of TGF‐β1 and collagen type I using immunohistochemical analysis. Results We detected strong expression of TGFβ‐RI and TGFβ‐RII on epidermis and epidermal appendages, moderate expression in vascular endothelial cells, smooth muscle cells and neural tissues, and weak expression in fibroblasts in normal skin sections. The expression levels of TGFβ‐RI and TGFβ‐RII were elevated in the tissue sections of DF in comparison with normal dermal sections using in situ hybridization and immunohistochemical staining. Furthermore, the expression of TGFβ‐RI and TGFβ‐RII was strong in spindle‐shaped cells around DF. The expression of TGFβ‐RI and TGFβ‐RII was decreased in DFSP in comparison with DF, and their expression was found to be homogeneous in each DFSP tumour cell. The staining for TGF‐β1 was found prominently on matrix and spindle‐shaped tumour cells of DF, and peripheral regions of DFSP. Weak expression of TGF‐β1 was found on normal skin or tumour cells in the central part of DFSP. Type I collagen expression was found on spindle‐shaped tumour cells in DF, but not in tumour cells of DFSP. Conclusions These results suggest the possibility that TGF‐β signalling may contribute to the fibrosis around DF, and that TGF‐β receptors may play important roles in TGF‐β signalling. The expression patterns of TGFβ‐RI and TGFβ‐RII may be helpful in distinguishing these diseases.